<DOC>
	<DOC>NCT02886598</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.</brief_summary>
	<brief_title>Safety and Efficacy of Firmagon® (Degarelix) for Injection</brief_title>
	<detailed_description />
	<criteria>Patients who are eligible for the treatment of Firmagon® (degarelix) for injection according to the approved product label, and Firmagon® (degarelix) treatment decided before study enrolment. Moreover, patient should have not previously received Firmagon® (degarelix) for injection before the study commencement date at each site. Indication: treatment of advanced, hormonedependent prostate cancer. Patients with previous or concurrent known hypersensitivity to any component of the drug.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>